Among numerous immunomodulatory agents, programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) checkpoint inhibitors have been proven effective in those patients with metastatic HNSCC (16–18). This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.